Japan Benign Prostatic Hyperplasia Treatment Market Market Size Report 2026-2034

Japan Benign Prostatic Hyperplasia Treatment Market Size

Japan Benign Prostatic Hyperplasia Treatment Market size is projected at USD 512.14 million in 2026 and is expected to hit USD 797.45 million by 2034 with a CAGR of 5.72%. The market was valued at USD 484.56 million in 2025, establishing a strong base for pharmaceutical, surgical, and minimally invasive therapies. Detailed treatment, end-use, patient-age, distribution-channel, and competitive data are increasingly required to assess commercialization opportunities and evolving treatment pathways.

Key Takeaways

Pharmacological treatment dominates treatment types with USD 204.62 million in 2026, representing approximately 40.0% of the treatment-type total, and is forecast to reach USD 315.69 million by 2034.
Surgical treatment records the fastest supplied treatment-type CAGR at 5.79%, increasing from USD 151.84 million in 2026 to USD 238.20 million by 2034.
Hospitals dominate end use with USD 246.94 million in 2026, approximately 48.2% of the corresponding 2026 market base, and are forecast at USD 392.10 million by 2034.
Clinics are the second-largest end-use category at USD 133.82 million in 2026 and USD 209.61 million in 2034, recording a 5.77% CAGR.
Japan is the sole country covered by the supplied dataset; therefore, an evidence-based separate emerging country forecast or fastest-growing regional market share cannot be calculated without introducing unsupported figures.

The market encompasses pharmacological management, conventional surgery, minimally invasive procedures, lifestyle intervention, and active surveillance for benign enlargement of the prostate and associated lower urinary tract symptoms. In 2026, pharmacological treatment contributes approximately 40.0% of the USD 512.14 million treatment-type total, surgical treatment 29.6%, minimally invasive procedures 19.8%, and other treatments 10.6%. Hospitals account for approximately 48.2% of the supplied end-use total, followed by clinics at 26.1%, ambulatory surgical centres at 15.6%, and specialty urology centers at 10.1%. Japan's 2025 population was approximately 123.05 million, while the country's aging profile remains particularly significant for BPH care.

Source: Company Publications, Primary Interviews, and skymarketinsights Analysis

Explore more data points, trends and opportunities Download Free Sample Report

Japan Benign Prostatic Hyperplasia Treatment Market Trends

Shift Toward Minimally Invasive and Endoscopic Treatment

Japan's demographic structure is accelerating demand for lower-burden BPH interventions. People aged 65 and above numbered 36.19 million in 2025 and represented 29.4% of the population, while Japan's total population declined by 2.5% between the 2020 and 2025 censuses. These demographic conditions are strengthening clinical requirements for therapies suitable for older patients with multiple comorbidities.

Technology adoption is moving toward endoscopic enucleation, laser systems, prostatic urethral lift and water-vapour energy therapy. Japanese clinical literature reports that endoscopic enucleation has become the country's most commonly performed surgical approach for BPH in recent years, while Rezūm water-vapour therapy has been approved in Japan since September 2022. A 2026 Japanese study evaluated 80 consecutive Rezūm patients, including 37 patients, or 46.2%, who continued antithrombotic therapy perioperatively.

Japan Benign Prostatic Hyperplasia Treatment Market Drivers

Rapid Aging and Expanding Treatment-Eligible Population

Japan's elderly population creates a structurally large patient pool for BPH diagnosis and intervention. In 2024, 36.24 million residents were aged 65+, equivalent to 29.3% of the population; the proportion reached 29.4% in 2025. With total population at 123.05 million in 2025 and approximately 90.6% of municipalities recording population declines since 2020, healthcare resources are increasingly oriented toward chronic and age-associated disorders.

Japan Benign Prostatic Hyperplasia Treatment Market Restraints

Treatment Morbidity and Patient Selection Requirements

Procedure-associated catheterization, bleeding, temporary urinary difficulties and sexual-function concerns can delay escalation from medication. Rezūm causes temporary prostate swelling and may require balloon catheter placement, while prostate shrinkage develops over approximately 3–6 months. In a Japanese cohort of 80 patients, 37, or 46.2%, remained on antithrombotic therapy, illustrating the complexity of treating older, medically complicated patients.

Japan Benign Prostatic Hyperplasia Treatment Market Opportunities

Expansion of Minimally Invasive Treatment Platforms

The opportunity is increasingly centered on treatments positioned between long-term medication and tissue-removing surgery. Rezūm has been available following its September 2022 Japanese approval and has demonstrated effectiveness extending to 5 years in referenced clinical evidence. Japan's 36.19 million people aged 65+ and 29.4% elderly population share provide a substantial demographic foundation for technologies emphasizing reduced invasiveness and shorter recovery.

Challenges in Japan Benign Prostatic Hyperplasia Treatment Market

Balancing Durability, Safety and Healthcare Capacity

Providers must balance therapeutic durability against perioperative burden as the patient population ages. Japan's overall population fell 2.5% between 2020 and 2025, while 1,558 of 1,719 municipalities, or 90.6%, recorded population declines. At the same time, the elderly population accounts for 29.4% of residents, increasing pressure on specialist urology capacity and requiring careful selection among medication, laser surgery, TURP and minimally invasive alternatives.

Report Scope

Report Metric	Details
Market Size in 2025	USD 484.56 Million
Market Size in 2026	USD 512.14 Million
Market Size in 2034	USD 797.45 Million
CAGR	5.72% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Report Coverage	Revenue Forecast, Competitive Landscape, Supply Chain Disruption, Growth Factors, Environment & Regulatory Landscape and Trends

Explore more data points, trends and opportunities Download Free Sample Report

Japan Benign Prostatic Hyperplasia Treatment Market Segmentation

Treatment type is led by pharmacological therapy at approximately 40.0% of the 2026 treatment-type total, while hospitals account for approximately 48.2% of the corresponding end-use base.

By Treatment Type

Pharmacological treatment is the largest category, valued at USD 193.82 million in 2025 and USD 204.62 million in 2026, before reaching USD 315.69 million in 2034 at a 5.57% CAGR. Alpha-blockers including tamsulosin, silodosin, alfuzosin and doxazosin remain central alongside 5-ARIs, PDE5 inhibitors and combination regimens.

Surgical treatment is the fastest-growing supplied treatment category with a 5.79% CAGR, rising from USD 151.84 million in 2026 to USD 238.20 million by 2034. Minimally invasive procedures grow at 5.74%, while other treatments advance at 5.78%, supporting continued diversification beyond pharmacotherapy.

By End Use

Hospitals constitute the largest end-use category at USD 233.07 million in 2025 and USD 246.94 million in 2026, reaching USD 392.10 million by 2034 at a 5.95% CAGR. Their approximately 48.2% 2026 contribution reflects access to surgery, anesthesia, imaging and inpatient management.

Among the supplied end-use categories, hospitals also carry the highest CAGR at 5.95%. Clinics expand at 5.77%, ambulatory surgical centres at 5.56%, and specialty urology centers at 5.60%, with the latter reaching USD 80.08 million by 2034.

By Patient Age Group

The market is segmented into below 50 years, 50–60 years and above 60 years. Japan's aging structure supports particularly strong clinical relevance for the above-60 cohort; people aged 65+ already represented 29.4% of the national population in 2025.

No market-value or CAGR table was supplied for patient-age subsegments. Consequently, numerical subsegment size, largest-subsegment CAGR and fastest-growing-subsegment CAGR cannot be stated without creating unsupported estimates.

By Distribution Channel

Distribution comprises hospital pharmacy, retail pharmacy and online pharmacy channels. Pharmaceutical therapy represents USD 204.62 million in 2026 and USD 315.69 million in 2034, supporting continued prescription dispensing requirements across these channels.

The supplied tables do not allocate revenue or CAGR among hospital, retail and online pharmacies. Therefore, no defensible largest-channel value or fastest-growing-channel CAGR can be calculated from the mandatory dataset.

Japan Benign Prostatic Hyperplasia Treatment Market Segmentations

By Treatment Type

Pharmacological treatment
- Alpha-blockers
- 5-alpha reductase inhibitors (5-ARI)
- Combination therapy
- Phosphodiesterase-5 inhibitors (pde5 inhibitors)
- Herbal and other drugs
Surgical treatment
- Transurethral resection of the prostate (TURP)
- Transurethral incision of the prostate (TUIP)
- Open prostatectomy
- Laser therapy
Minimally invasive procedures
- Urolift system
- RezÅ«m water vapour therapy
- Prostatic artery embolisation
- Microwave thermotherapy
- Transurethral needle ablation (TUNA)
Other treatments
- Lifestyle modifications
- Watchful waiting / active surveillance

By End Use

Hospitals
Clinics
Ambulatory surgical centres
Specialty urology centers

By Patient Age Group

Below 50 years
50–60 years
Above 60 years

By Distribution Channel

Hospital pharmacy
Retail pharmacy
Online pharmacy

Japan Benign Prostatic Hyperplasia Treatment Market Counties Outlook

Japan's 2025 population totaled 123.05 million. Tokyo had 14.246 million residents, while Tokyo, Kanagawa, Saitama and Chiba collectively contained 36.986 million people, equivalent to 30.1% of Japan's population. These densely populated prefectures provide substantial concentration of hospitals, specialist care demand and potential BPH treatment volumes.

At the broader national level, Tokyo, Kanagawa, Osaka, Aichi and Saitama accounted for 37.9% of Japan's population in 2024. The mandatory dataset does not provide prefectural BPH revenues, production volumes or regional CAGR figures; accordingly, national market values cannot be redistributed geographically without unsupported assumptions.

Regional Growth Insights Download Free Sample

Top players in Japan Benign Prostatic Hyperplasia Treatment Market

Astellas Pharma Inc.
Kissei Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
Tsumura & Co.
Olympus Corporation
Boston Scientific Corporation
Teleflex Incorporated
Terumo Corporation
Pfizer Inc.
GSK plc
Eli Lilly and Company
Boehringer Ingelheim

Top Two Companies

Astellas Pharma Inc. Exact Japan BPH revenue share is not disclosed in the supplied dataset and therefore cannot be represented as a defensible percentage. Astellas nevertheless has established relevance in Japanese urology and appears among companies associated with contemporary Japanese BPH clinical research. A 2026 multicenter Japanese UroLift registry disclosure identifies relationships involving Astellas, Kissei, Kyorin, Teleflex and Boston Scientific among participating investigators. Its positioning benefits from established pharmaceutical commercialization infrastructure and familiarity with Japanese urology care.
Kissei Pharmaceutical Co., Ltd. A verified company-specific percentage share is likewise unavailable from the mandatory market tables. Kissei maintains recognizable positioning within Japan's urology ecosystem, including association with investigators participating in recent real-world BPH research. Competitive differentiation increasingly depends on physician relationships, pharmacological portfolios, evidence generation and the ability to participate in treatment pathways that increasingly combine medical management with minimally invasive or surgical escalation.

Recent Developments in Japan Benign Prostatic Hyperplasia Treatment Market

2026:A multicenter real-world Japanese registry study reported clinical evidence concerning the UroLift prostatic urethral lift system in BPH patients.
2026:Japanese investigators published evidence involving 80 consecutive Rezūm patients treated between August 2023 and July 2024, including 37 patients continuing antithrombotic therapy.
2025:The Japanese Journal of Endourology and Robotics published an updated review of the Rezūm system, highlighting its position as a minimally invasive surgical treatment using water-vapour energy.
2025:Japanese clinical literature emphasized that endoscopic enucleation had become the most commonly performed BPH surgical procedure in Japan in recent years.
2025:National demographic statistics showed Japan's population aged 65+ at 36.19 million, representing a record 29.4% of the population and reinforcing the long-term BPH treatment requirement.

Research Methodology

The analysis uses the supplied 2025, 2026 and 2034 market tables as the mandatory quantitative source for treatment-type and end-use values, contributions and CAGR calculations. Treatment-type totals of USD 484.56 million in 2025, USD 512.14 million in 2026 and USD 797.45 million in 2034 are retained exactly as provided. The separate end-use table reports USD 512.70 million in 2026 and USD 805.36 million in 2034; this source-level discrepancy is preserved rather than artificially reconciled. Secondary evidence was used only for demographic, technology, clinical and competitive context, while unsupported regional, age-group, distribution-channel and company-share figures were not fabricated.

Frequently Asked Questions

What is the Japan Benign Prostatic Hyperplasia Treatment Market size in 2026?

The Japan Benign Prostatic Hyperplasia Treatment Market is projected to reach USD 512.14 million in 2026.

What is the forecast size of the Japan Benign Prostatic Hyperplasia Treatment Market by 2034?

The Japan Benign Prostatic Hyperplasia Treatment Market is expected to reach USD 797.45 million by 2034.

What is the CAGR of the Japan Benign Prostatic Hyperplasia Treatment Market from 2026 to 2034?

The Japan Benign Prostatic Hyperplasia Treatment Market is projected to grow at a CAGR of 5.72% from 2026 to 2034.

Which segment dominates the Japan Benign Prostatic Hyperplasia Treatment Market?

Pharmacological treatment dominates the treatment-type segment with USD 204.62 million in 2026, representing approximately 40.0% of treatment revenue. Hospitals dominate the end-use segment with USD 246.94 million, accounting for approximately 48.2% of the corresponding 2026 market base.

Who are the top players in the Japan Benign Prostatic Hyperplasia Treatment Market?

Top players include Astellas Pharma Inc., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Tsumura & Co., Olympus Corporation, Boston Scientific Corporation, Teleflex Incorporated, Terumo Corporation, Pfizer Inc., GSK plc, Eli Lilly and Company, and Boehringer Ingelheim.

Author: Jenny Burkett

Senior Market Research Analyst | 8 Years Experience | Digital Therapeutics and Connected Medical Devices

Jenny specializes in digital therapeutics, remote monitoring devices and healthcare IT platforms. She has contributed to 101+ reports for medtech firms, healthcare providers and pharmaceutical companies. Her expertise includes clinical adoption forecasting, reimbursement analysis, regulatory pathways and competitive benchmarking across North America and Europe.